Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer

Metaplastic breast cancer (MBC) is a rare and aggressive subtype of breast cancer. Tumor characteristics typically feature estrogen receptor, progesterone receptor, and HER2-negative, triple-negative breast cancer (TNBC), with a poorer prognosis relative to pure invasive ductal or lobular disease. R...

Descripción completa

Detalles Bibliográficos
Autores principales: Gorshein, Elan, Matsuda, Kant, Riedlinger, Gregory, Sokol, Levi, Rodriguez-Rodriguez, Lorna, Eladoumikdachi, Firas, Grandhi, Miral, Ganesan, Shridar, Toppmeyer, Deborah L., Potdevin, Lindsay, Toomey, Kathleen, Hirshfield, Kim M., Chan, Nancy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255711/
https://www.ncbi.nlm.nih.gov/pubmed/34248561
http://dx.doi.org/10.1159/000515510

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255711/
https://www.ncbi.nlm.nih.gov/pubmed/34248561
http://dx.doi.org/10.1159/000515510

Ejemplares similares